UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 5, 2007
Renhuang Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Nevada
(State or Other Jurisdiction of Incorporation)
0-24512 88-1273503
(Commission File Number) (IRS Employer Identification Number)
No. 281, Taiping Road, Taiping District,
Harbin, Heilongjiang Province, 150050
P. R. China
(Address of Principal Executive Offices)
+86-451-5762-0378
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 7.01 Regulation FD Disclosure.
-------------------------
On February 5, 2007, Renhuang Pharmaceuticals, Inc (the "Company") issued a
press release, a copy of which is attached as Exhibit 99.1 to this report and
is being furnished to the SEC and shall not be deemed "filed" for any purpose.
Item 9.01 Financial Statements, Pro Form Financial Information and Exhibits.
(c) Exhibits.
EXHIBITS
Exhibit Description
------- ----------------------------------------------
99.1 Press Release dated February 5, 2007.
--------------------------------------------------------------------------------
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Renhuang Pharmaceuticals, Inc.
Date: February 5, 2007 By: /s/ Shaoming Li
----------------------------------------
Shaoming Li
Chief Executive Officer and President
--------------------------------------------------------------------------------